Cervical Cancer in SAARC Countries.

IF 0.6 Q4 ONCOLOGY
South Asian Journal of Cancer Pub Date : 2023-02-25 eCollection Date: 2023-01-01 DOI:10.1055/s-0043-1764227
Purvish M Parikh, Sujith Kumar Mullapally, Sachin Hingmire, A F M Kamal Uddin, M M Thinn, Arun Shahi, Ugyen Tshomo, Indu Mohan, Satinder Kaur, Nikhil Ghadyalpatil
{"title":"Cervical Cancer in SAARC Countries.","authors":"Purvish M Parikh, Sujith Kumar Mullapally, Sachin Hingmire, A F M Kamal Uddin, M M Thinn, Arun Shahi, Ugyen Tshomo, Indu Mohan, Satinder Kaur, Nikhil Ghadyalpatil","doi":"10.1055/s-0043-1764227","DOIUrl":null,"url":null,"abstract":"<p><p>Purvish M. ParikhIn the year 2020, a total of 342 000 women were estimated to die of cervical cancer, of which 90%) were expected amongst low- and middle-income countries (LMIC). Globally incidence of cervical cancer has reduced as a result of improved personal hygiene, better living conditions and higher application of opportunistic screening programs. Yet GLOBOCAN shows that absolute number of cases are still increasing. We therefore conducted a 21 question multiple choice questionnaire online survey in Jan 2023 amongst 9 SAARC countries. A total of 367 replies were received and the representative answers for each country are being reported in this manuscript. A good possibility of achieving World Health Assembly target (Nov 17, 2020) was felt only by Bhutan and Nepal. For screening, most countries (Bhutan, India, Myanmar, Nepal, Pakistan and Sri Lanka) recommend for all asymptomatic eligible patients. Public health experts have suggested VIA / VILI as the best solution for LMICs. However, a dual screening strategy (HPV DNA plus) cytology was preferred by doctors in Afghanistan, Bhutan, India, Myanmar, Pakistan and Sri Lanka. Screening, triage and then treatment was the preferred by Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka. HPV vaccination was recommended in all girls between ages 10 to 26 years in Bangladesh, India, Myanmar, Nepal, Pakistan and Sri Lanka. All the 9 countries would use HPV vaccination to all eligible patients if the cost of the vaccine was reasonably low. Our survey clearly outlines challenges faced in tackling cervical cancer in SAARC countries. We also provide consensus regarding several potential solutions that can be used in both public and private cervical cancer control programs.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"12 1","pages":"1-8"},"PeriodicalIF":0.6000,"publicationDate":"2023-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/c5/10-1055-s-0043-1764227.PMC9966176.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Asian Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1764227","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purvish M. ParikhIn the year 2020, a total of 342 000 women were estimated to die of cervical cancer, of which 90%) were expected amongst low- and middle-income countries (LMIC). Globally incidence of cervical cancer has reduced as a result of improved personal hygiene, better living conditions and higher application of opportunistic screening programs. Yet GLOBOCAN shows that absolute number of cases are still increasing. We therefore conducted a 21 question multiple choice questionnaire online survey in Jan 2023 amongst 9 SAARC countries. A total of 367 replies were received and the representative answers for each country are being reported in this manuscript. A good possibility of achieving World Health Assembly target (Nov 17, 2020) was felt only by Bhutan and Nepal. For screening, most countries (Bhutan, India, Myanmar, Nepal, Pakistan and Sri Lanka) recommend for all asymptomatic eligible patients. Public health experts have suggested VIA / VILI as the best solution for LMICs. However, a dual screening strategy (HPV DNA plus) cytology was preferred by doctors in Afghanistan, Bhutan, India, Myanmar, Pakistan and Sri Lanka. Screening, triage and then treatment was the preferred by Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka. HPV vaccination was recommended in all girls between ages 10 to 26 years in Bangladesh, India, Myanmar, Nepal, Pakistan and Sri Lanka. All the 9 countries would use HPV vaccination to all eligible patients if the cost of the vaccine was reasonably low. Our survey clearly outlines challenges faced in tackling cervical cancer in SAARC countries. We also provide consensus regarding several potential solutions that can be used in both public and private cervical cancer control programs.

Abstract Image

Abstract Image

南亚区域合作联盟国家的宫颈癌。
Purvish M. Parikh 2020 年,估计共有 34.2 万名妇女死于宫颈癌,其中 90% 预计死于中低收入国家(LMIC)。由于个人卫生的改善、生活条件的改善以及机会性筛查计划的推广,全球宫颈癌的发病率有所下降。然而,GLOBOCAN 显示,病例的绝对数量仍在增加。因此,我们于 2023 年 1 月在南亚区域合作联盟(SAARC)的 9 个国家中开展了一项 21 题多选问卷在线调查。共收到 367 份回复,本手稿将报告每个国家的代表性答案。只有不丹和尼泊尔认为很有可能实现世界卫生大会的目标(2020 年 11 月 17 日)。在筛查方面,大多数国家(不丹、印度、缅甸、尼泊尔、巴基斯坦和斯里兰卡)建议对所有符合条件的无症状患者进行筛查。公共卫生专家建议将 VIA / VILI 作为 LMIC 的最佳解决方案。然而,阿富汗、不丹、印度、缅甸、巴基斯坦和斯里兰卡的医生更倾向于采用双重筛查策略(HPV DNA 加)细胞学检查。孟加拉国、不丹、印度、马尔代夫、尼泊尔、巴基斯坦和斯里兰卡则倾向于筛查、分流和治疗。孟加拉国、印度、缅甸、尼泊尔、巴基斯坦和斯里兰卡建议所有 10 至 26 岁的女孩接种 HPV 疫苗。如果疫苗费用合理低廉,所有这 9 个国家都会为所有符合条件的患者接种人乳头瘤病毒疫苗。我们的调查清楚地概述了南亚区域合作联盟国家在应对宫颈癌方面所面临的挑战。我们还就可用于公共和私营宫颈癌控制计划的几种潜在解决方案达成了共识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
80
审稿时长
35 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信